

Supporting Information

# A new dimeric copper(II) complex of hexyl bis(pyrazolyl)acetate ligand as efficient catalyst for allylic oxidations

Luca Bagnarelli <sup>1</sup>, Alessandro Dolmella <sup>2</sup>, Carlo Santini <sup>1</sup>, Riccardo Vallesi <sup>1</sup>, Roberto Giacomantonio <sup>1</sup>,  
Serena Gabrielli <sup>1,\*</sup> and Maura Pellei <sup>1,\*</sup>

<sup>1</sup> School of Science and Technology, Chemistry Division, University of Camerino, via S. Agostino 1, 62032 Camerino, Italy; luca.bagnarelli@unicam.it (L.B.); carlo.santini@unicam.it (C.S.); riccardo.vallesi@unicam.it (R.V.); robert.giacomantonio@unicam.it (R.G.)

<sup>2</sup> Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, 35131 Padova, Italy; alessandro.dolmella@unipd.it

\* Correspondence: serena.gabrielli@unicam.it (S.G.); maura.pellei@unicam.it (M.P.);  
Tel.: +39-0737-402219 (S.G.); +39-0737-402213 (M.P.)

## Contents

**Table S1:** Summary of crystal data and structure refinement for compound **1**.

**Table S2:** Intermolecular contacts in **1**.

**Figure S1:** ORTEP drawing of the asymmetric unit of **1**, showing part of the selected numbering scheme.

**Figure S2:** ORTEP representation of the dimeric complex **1** showing part of the selected numbering scheme.

**Figure S3:** Packing diagrams for **1**.

**Figure S4:** <sup>1</sup>H-NMR of HC(COOHex)(pz)<sub>2</sub> (L<sup>OHex</sup>) in CDCl<sub>3</sub>.

**Figure S5:** <sup>13</sup>C-NMR of HC(COOHex)(pz)<sub>2</sub> (L<sup>OHex</sup>) in CDCl<sub>3</sub>.

**Figure S6:** FT-IR spectrum of HC(COOHex)(pz)<sub>2</sub> (L<sup>OHex</sup>).

**Figure S7:** ESI-MS(+) spectrum of HC(COOHex)(pz)<sub>2</sub> (L<sup>OHex</sup>).

**Figure S8:** FT-IR spectrum of [Cu(L<sup>OHex</sup>)Br(μ-Br)]<sub>2</sub> (**1**).

**Figure S9:** ESI-MS(+) spectrum of [Cu(L<sup>OHex</sup>)Br(μ-Br)]<sub>2</sub> (**1**).

**Figure S10:** <sup>1</sup>H-NMR of compound **4** in CDCl<sub>3</sub>.

**Figure S11:** <sup>13</sup>C-NMR of compound **4** in CDCl<sub>3</sub>.

**Figure S12:** FT-IR spectrum of compound **4**.

**Figure S13:** <sup>1</sup>H-NMR of compound **5** in CDCl<sub>3</sub>.

**Figure S14:** <sup>13</sup>C-NMR of compound **5** in CDCl<sub>3</sub>.

**Figure S15:** FT-IR spectrum of compound **5**.

**Figure S16:** <sup>1</sup>H-NMR of compound **6** in CDCl<sub>3</sub>.

**Figure S17:** <sup>13</sup>C-NMR of compound **6** in CDCl<sub>3</sub>.

**Figure S18:** FT-IR spectrum of compound **6**.

**Table S1.** Summary of crystal data and structure refinement for compound **1**.


Empirical formula	<b>C<sub>14</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>CuBr<sub>2</sub></b>
Formula weight	499.70
Temperature / K	296.9(9)
Crystal system	monoclinic
Space group	<i>P</i> 2 <sub>1</sub> / <i>c</i>
<i>a</i> / Å	13.0171(4)
<i>b</i> / Å	9.8111(2)
<i>c</i> / Å	15.8632(4)
$\alpha$ / °	90
$\beta$ / °	110.248(3)
$\gamma$ / °	90
Volume / Å <sup>3</sup>	1900.73(9)
<i>Z</i>	4
$\rho_{\text{calc}}$ g/cm <sup>3</sup>	1.746
$\mu$ / mm <sup>-1</sup>	5.366
<i>F</i> (000)	988.0
Crystal size / mm <sup>3</sup>	0.6 × 0.4 × 0.01
Radiation	Mo K $\alpha$ ( $\lambda$ = 0.71073)
Index ranges	−15 ≤ <i>h</i> ≤ 17, −13 ≤ <i>k</i> ≤ 12, −19 ≤ <i>l</i> ≤ 20
Reflections collected	22513
Independent reflections / <i>R</i> <sub>int</sub>	4228 / 0.0437
Data / restraints / parameters	4228 / 78 / 293
Goodness-of-fit on <i>F</i> <sup>2</sup>	1.058
Final <i>R</i> indexes [ <i>I</i> ≥ 2 $\sigma$ ( <i>I</i> )]	<i>R</i> <sub>1</sub> = 0.0351, <i>wR</i> <sub>2</sub> = 0.0666
Largest diff. peak / hole / e Å <sup>-3</sup>	0.50 / −0.46

<sup>a</sup> Goodness-of-fit =  $[\sum w (F_o^2 - F_c^2)^2 / (N_{\text{obs}} - N_{\text{params}})]^{1/2}$ , based on all data; <sup>b</sup>  $R_1 = \sum ||F_o| - |F_c|| / \sum |F_o|$ ; <sup>c</sup>  $wR_2 = [\sum w (F_o^2 - F_c^2)^2 / \sum w (F_o^2)^2]^{1/2}$ .


**Table S2.** Intermolecular contacts in **1**.

Atom (A)	Atom (B)	A...B (Å)	Symmetry <sup>a</sup>
C(8)	Br(1)	3.37	1 − <i>x</i> , −1/2 + <i>y</i> , 3/2 − <i>z</i>
C(7)	Br(1)	3.43	1 − <i>x</i> , −1/2 + <i>y</i> , 3/2 − <i>z</i>
H(7)	Br(1)	2.91	1 − <i>x</i> , −1/2 + <i>y</i> , 3/2 − <i>z</i>
H(1)	Br(1)	2.93	<i>x</i> , −1 + <i>y</i> , <i>z</i>


<sup>a</sup> Symmetry operator of B atom; atom A belongs to asymmetric unit.




**Figure S1.** ORTEP drawing of the asymmetric unit of **1**, showing part of the selected numbering scheme. Hydrogen atoms omitted for clarity. The alternate arrangement of the disordered hexyloxy chain has dashed bonds. Thermal ellipsoids drawn at the 50% probability level.



**Figure S2.** An ORTEP representation of the dimeric complex **1** showing part of the selected numbering scheme. Hydrogen atoms and disordered hexyloxy chains removed for clarity. Thermal ellipsoids drawn at the 50% probability level.



**Figure S3.** Packing diagrams for **1**. Left: the bi-dimensional network developing in the *bc* plane (view down the *a* axis). Right: the 'sandwich' motif created by the planes incorporating the hexyl aliphatic chains and the part of the molecules containing the  $\text{Cu}_2\text{Br}_2$  tetramers developing along the *a* axis. Contacts colored in cyan.



**Figure S4.**  $^1\text{H}$ -NMR of  $\text{HC}(\text{COOHex})(\text{pz})_2$  ( $\text{L}^{\text{OHex}}$ ) in  $\text{CDCl}_3$ .




Figure S5.  $^{13}\text{C}$ -NMR of  $\text{HC}(\text{COOHex})(\text{pz})_2$  ( $\text{L}^{\text{OHex}}$ ) in  $\text{CDCl}_3$ .





Figure S6. FT-IR spectrum of  $\text{HC}(\text{COOHex})(\text{pz})_2 (\text{LOHex})$ .



**Figure S7.** ESI-MS(+) spectrum of  $\text{HC}(\text{COOHex})(\text{pz})_2$  ( $\text{LOHex}$ ).




Figure S8. FT-IR spectrum of  $[\text{Cu}(\text{LOHex})\text{Br}(\mu\text{-Br})]_2$  (1).






Figure S9. ESI-MS(+) spectrum of  $[\text{Cu}(\text{LOHex})\text{Br}(\mu\text{-Br})]_2$  (1).




Figure S10. <sup>1</sup>H-NMR of compound **4** in CDCl<sub>3</sub>.




Figure S11.  $^{13}\text{C}$ -NMR of compound **4** in  $\text{CDCl}_3$ .




Figure S12. FT-IR spectrum of compound 4.




Figure S13. <sup>1</sup>H-NMR of compound 5 in CDCl<sub>3</sub>.




Figure S14.  $^{13}\text{C}$ -NMR of compound 5 in  $\text{CDCl}_3$ .




Figure S15. FT-IR spectrum of compound 5.




Figure S16. <sup>1</sup>H-NMR of compound 6 in CDCl<sub>3</sub>.






Figure S17.  $^{13}\text{C}$ -NMR of compound 6 in  $\text{CDCl}_3$ .




Figure S18. FT-IR spectrum of compound 6.